{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:42:37Z","timestamp":1793853757468,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1245\/s10434-024-15646-6","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T09:02:05Z","timestamp":1721034125000},"page":"6262-6273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei"],"prefix":"10.1245","volume":"31","author":[{"given":"Shigeki","family":"Kusamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Delhorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Taibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rea Lo","family":"Dico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"15646_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69\u201376.","journal-title":"Lancet Oncol."},{"key":"15646_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","volume":"19","author":"F Pietrantonio","year":"2014","unstructured":"Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014;19:845\u201350.","journal-title":"Oncologist."},{"key":"15646_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","volume":"99","author":"AL Farquharson","year":"2008","unstructured":"Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99:591\u20136.","journal-title":"Br J Cancer."},{"key":"15646_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.5858\/2002-126-0837-ENOTAA","volume":"126","author":"NJ Carr","year":"2002","unstructured":"Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an a-lysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837\u201341.","journal-title":"Arch Pathol Lab Med."},{"key":"15646_CR5","unstructured":"Carr N, Sobin L. Tumors of the appendix. In: Bosman FT, Carneiro F, Hruban RH, et al. editors. WHO Classification of tumours of the digestive system. World Health Organization classification of tumours, vol. 3, ed. 4. Lyon: IARC Press; 2010. p 122\u20135."},{"key":"15646_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/annonc\/mdw314","volume":"27","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Perrone F, Mennitto A, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016;27:2097\u2013103.","journal-title":"Ann Oncol."},{"key":"15646_CR7","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"27","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonmura Y. PSOGI, RENAPE The role of HIPEC in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;27:e206363.","journal-title":"JAMA Surg."},{"issue":"4","key":"15646_CR8","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1245\/s10434-022-12990-3","volume":"30","author":"S Kusamura","year":"2023","unstructured":"Kusamura S, Bhatt A, Hubner M, Villeneuve L, Deraco M, Bakrin N, Van Der Speeten K, Glehen O. The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: methodology. Ann Surg Oncol. 2023;30(4):2508\u201319.","journal-title":"Ann Surg Oncol."},{"key":"15646_CR9","doi-asserted-by":"crossref","unstructured":"Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. 2021;47(1):4\u201310.","DOI":"10.1016\/j.ejso.2019.03.012"},{"key":"15646_CR10","doi-asserted-by":"publisher","first-page":"924e6","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924e6.","journal-title":"BMJ."},{"key":"15646_CR11","first-page":"1490e4","volume":"328","author":"Grades of Recommendation. Assessment, development, and evalution (GRADE) working group","year":"2004","unstructured":"Grades of Recommendation. Assessment, development, and evalution (GRADE) working group. Education and debate e grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490e4.","journal-title":"BMJ."},{"key":"15646_CR12","doi-asserted-by":"publisher","first-page":"395e400","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64:395e400.","journal-title":"J Clin Epidemiol."},{"key":"15646_CR13","first-page":"359e63","volume":"66","author":"X Huang","year":"2006","unstructured":"Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc. 2006;66:359e63.","journal-title":"AMIA Annu Symp Proc."},{"key":"15646_CR14","first-page":"407e15","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G. GRADE guidelines: 4. Rating the quality of evidence e study limitations (risk of bias). J Clin Epidemiol. 2011;64:407e15.","journal-title":"J Clin Epidemiol."},{"key":"15646_CR15","first-page":"719e25","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Guyatt GH, Oxman AD. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719e25.","journal-title":"J Clin Epidemiol."},{"key":"15646_CR16","first-page":"726e35","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD. GRADE guidelines: 15. Going from evidence to recommendation e determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol. 2013;66:726e35.","journal-title":"J Clin Epidemiol."},{"issue":"366","key":"15646_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(366):l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ."},{"issue":"9","key":"15646_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"Karem Slim","year":"2003","unstructured":"Slim Karem, Nini Emile, Forestier Damien, Kwiatkowski Fabrice, Panis Yves, Chipponi Jacques. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg."},{"issue":"4","key":"15646_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434\u201343.","journal-title":"J Am Coll Surg."},{"issue":"3","key":"15646_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven O, Votanopoulos KI, Shen P, Mansfield P, Bartlett DL, Russell G, et al. Health-related quality of life after cytoreductive surgery\/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann Surg Oncol. 2020;27(3):772\u201380.","journal-title":"Ann Surg Oncol."},{"key":"15646_CR21","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net F , Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, Facy O, C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J , Glehen O, UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;6:66.","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"15646_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/annonc\/mdh186","volume":"15","author":"D Elias","year":"2004","unstructured":"Elias D, Sideris L, Pocard M, et al. Efficacy of intraperitonealchemohyperthermia with Oxaliplatin in colorectal peritonealcarcinomatosis. Preliminary results in 24 patients. Ann Oncol. 2004;15:781\u20135.","journal-title":"Ann Oncol."},{"issue":"4","key":"15646_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med."},{"issue":"7","key":"15646_CR24","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/biomedicines11072049","volume":"11","author":"S Kusamura","year":"2023","unstructured":"Kusamura S, Busico A, Conca E, Capone I, Agnelli L, Lorenzini D, Brich S, Angelini M, Volpi CC, Trupia DV, Lagano V, Torelli T, Gloghini A, Baratti D, Guaglio M, Milione M, Deraco M, Perrone F. A2AR expression and immunosuppressive environment independent of KRAS and GNAS mutations in pseudomyxoma peritonei. Biomedicines. 2023;11(7):2049.","journal-title":"Biomedicines."},{"key":"15646_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109166","volume":"111","author":"N Nevo","year":"2022","unstructured":"Nevo N, Lee Goldstein A, Bar-David S, Natanson M, Alon G, Lahat G, Nizri E. Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma. Int Immunopharmacol. 2022;111:109166. https:\/\/doi.org\/10.1016\/j.intimp.2022.109166.","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"15646_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/02656736.2021.1945688","volume":"38","author":"CC Wu","year":"2021","unstructured":"Wu CC, Hsu YT, Chang CL. Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting. Int J Hyperthermia. 2021;38(1):1013\u201322. https:\/\/doi.org\/10.1080\/02656736.2021.1945688.","journal-title":"Int J Hyperthermia."},{"issue":"2","key":"15646_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/onc.2015.82","volume":"35","author":"B Zunino","year":"2016","unstructured":"Zunino B, Rubio-Pati\u00f1o C, Villa E, Meynet O, Proics E, Cornille A, Pommier S, Mondrag\u00f3n L, Chiche J, Bereder JM, Carles M, Ricci JE. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016;35(2):261\u20138. https:\/\/doi.org\/10.1038\/onc.2015.82. (Epub 2015 Apr 13).","journal-title":"Oncogene."},{"key":"15646_CR28","unstructured":"Frei E III, Eder JP. Combination chemotherapy. In: Kufe DW (ed) Holland\u2013Frei cancer medicine, 6th ed. Hamilton: BC Decker; 2003."},{"key":"15646_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jso.2930540209","volume":"54","author":"Y Saikawa","year":"1993","unstructured":"Saikawa Y, Kubota T, Kuo TH, et al. Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro. J Surg Oncol. 1993;54:98\u2013102.","journal-title":"J Surg Oncol."},{"key":"15646_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jso.2930560408","volume":"56","author":"Y Saikawa","year":"1994","unstructured":"Saikawa Y, Kubota T, Kuo TH, et al. Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice. J Surg Oncol. 1994;56:242\u20135.","journal-title":"J Surg Oncol."},{"key":"15646_CR31","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1245\/s10434-007-9429-1","volume":"14","author":"S Kusamura","year":"2007","unstructured":"Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14:2550\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"15646_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/02656736.2014.893451","volume":"30","author":"RR Yarema","year":"2014","unstructured":"Yarema RR, Ohorchak MA, Zubarev GP, Mylyan YP, Oliynyk YY, Zubarev MG, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-center retrospective study. Int J Hyperthermia. 2014;30(3):159\u201365.","journal-title":"Int J Hyperthermia."},{"key":"15646_CR33","unstructured":"van der Speeten K, Kusamura S, Villeneuve L, Piso P, Verwaal V, Gonz\u00e1lez-Moreno, Glehen O. Proceedings of the Peritoneal Surface Oncology Group International (PSOGI) congress; 2023."},{"issue":"11","key":"15646_CR34","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","volume":"47","author":"VCJ van de Vlasakker","year":"2021","unstructured":"van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Go\u00e9r\u00e9 D, Gonz\u00e1lez-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, van der Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y, Glehen O, de Hingh IHJT. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47(11):2888\u201392.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"15646_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ejso.2016.03.017","volume":"42","author":"N Ansari","year":"2016","unstructured":"Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035\u201341.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"15646_CR36","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1245\/s10434-009-0341-8","volume":"16","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Smigielski ME, Zhu KJ, Keh MN, Zhao J, Morris DL. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16(7):1903\u201311.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"15646_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/01.sla.0000231705.40081.1a","volume":"245","author":"RM Smeenk","year":"2007","unstructured":"Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104\u20139.","journal-title":"Ann Surg."},{"issue":"13","key":"15646_CR38","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"AM Kuijpers","year":"2013","unstructured":"Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, Te Velde EA, Verwaal VJ. Cytoreduction and HIPEC in the Netherlands: -tionwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224\u201330.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"15646_CR39","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/cncr.32881","volume":"126","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer. 2020;126(11):2525\u201333. https:\/\/doi.org\/10.1002\/cncr.32881. (Epub 2020 Apr 13).","journal-title":"Cancer."},{"issue":"8","key":"15646_CR40","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1245\/s10434-007-9393-9","volume":"14","author":"D Baratti","year":"2007","unstructured":"Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14(8):2300\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9393-9.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"15646_CR41","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/bjs.6235","volume":"95","author":"D Elias","year":"2008","unstructured":"Elias D, Honor\u00e9 C, Ciuchend\u00e9a R, Billard V, Ray-rd B, Lo Dico R, Dromain C, Duvillard P, Go\u00e9r\u00e9 D. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95(9):1164\u201371.","journal-title":"Br J Surg."},{"key":"15646_CR42","doi-asserted-by":"publisher","unstructured":"Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ, PSOGI. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11\u201335. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.012.","DOI":"10.1016\/j.ejso.2020.02.012"},{"key":"15646_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.suronc.2019.03.004","volume":"29","author":"L Benhaim","year":"2019","unstructured":"Benhaim L, Faron M, Gelli M, Sourrouille I, Honor\u00e9 C, Delhorme JB, Elias D, Goere D. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol. 2019;29:78\u201383.","journal-title":"Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15646-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:29:24Z","timestamp":1722868164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15646-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["15646"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15646-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olivier Glehen is a consultant for Gamida and no other authors have any disclosures. The authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}